Presentation is loading. Please wait.

Presentation is loading. Please wait.

M. Rachel McDowell, RN, MSN, ACNP-BC Cancer Supportive Care Nurse Practitioner Vanderbilt-Ingram Cancer Center.

Similar presentations


Presentation on theme: "M. Rachel McDowell, RN, MSN, ACNP-BC Cancer Supportive Care Nurse Practitioner Vanderbilt-Ingram Cancer Center."— Presentation transcript:

1 M. Rachel McDowell, RN, MSN, ACNP-BC Cancer Supportive Care Nurse Practitioner Vanderbilt-Ingram Cancer Center

2 Goals of presentation Provide steps for developing treatment plan Approach to titration (upward and downward) Patient education Consent for treatment Utilization of controlled substance databases Urine drug screens use and interpretation

3 Benefits of pain control Earlier mobilization Shortened hospitalization Reduced cost Improved QOL Decrease in patient suffering

4 Pain Assessment Location Character Achy Sharp Jabbing Deep or Superficial Burning, tingling, numbness Duration: when did this begin? Frequency: constant, intermittent, am, pm?

5 Intensity: Pain Scale Lorne B. Yudcovitch, OD, MS, FAAO; College of Optometry, Pacific University; 2043 College Way; Forest Grove, OR The Use of Anesthetics, Steroids, Non-Steroidals, and Central-Acting Analgesics in the Management of Ocular Pain Retrieved from e002.jpg&imgrefurl=http://www.pacificu.edu/optometry/ce/courses/22746/ocularpainpg1.cfm&h=274&w=5 64&sz=37&tbnid=BdvVnqYJnZHq3M:&tbnh=65&tbnw=134&prev=/images%3Fq%3DPain%2BAssessment%2Bscal es&hl=en&usg=__TdhB- pWbp_ouIYHvwQ4FJ1dHzgw=&ei=BBR2S6T_IMGXtgeCnqSlCg&sa=X&oi=image_result&resnum=7&ct=image& ved=0CCEQ9QEwBg

6 Treatment Plan Goal of Therapy: Decrease pain level Pain is mostly controlled, most of the time Increase level of function Minimal side effects from regimen Time frame – acute or chronic

7 Important Factors Etiology of pain, prognosis Stage of disease – how aggressive do you want to be? What kind of pain or combo do they have? What have they been tried on in the past? How did it work for them, side effects, adverse events? Age, performance status History or current issue with drug misuse/abuse What kind of insurance do they have or not? How capable is the patient in understanding plan?

8 Treatment Options Treat underlying cause Non-pharmacological measures Pharmacological measures No single modality done in isolation will be effective for most patients with chronic noncancer pain (CNCP) (Ashburn, Staats, Lancet 1999)

9 Nonpharmacologic Options Biofeedback Relaxation therapy Physical and occupational therapy Cognitive/behavioral strategies Guided imagery Acupuncture Transcutaneous electrical nerve stimulation Positioning Rest, activity Massage Heat and cold

10 Treatment for pain Identify the cause of the pain Primary treatment if indicated Radiation Surgery Hyperbaric treatment Interventions: Nerve Block, Kyphoplasty Medications

11 Interventional Techniques Interventional Therapies Trigger points Acupuncture Nerve blocks Facet denervation Intrathecal pumps

12 Medications Somatic/Nociceptive Pain Opioids NSAIDS Neuropathic Pain Anticonvulsants Antidepressants - SNRIs Bony Pain NSAIDS Steroids

13 Pharmacotherapeutics and the Nervous System

14 Guidelines for opioids WHO ladder combined with etiology-specific therapies for syndromes pharmacologic and nonpharmacologic interventions long-acting + short-acting opioids adjuvant medications for neuropathic pain NSAIDs and steroids can be helpful when there is an inflammatory component to pain

15 WHO Guidelines for Cancer Pain Step 3: Opioids for moderate-to-severe pain +/- non-opioid +/-adjuvant therapy Step 2: Opioids for mild- to- moderate pain +/- non- opioid +/- adjuvant therapy Step 1: Non-opioid +/- adjuvant therapy STEP 1 STEP 2 STEP 3 GOAL: Freedom From Pain Pain Persists (Adapted from Portenoy et al, 1997)

16 Opioid Selection No perfect opioid Pre-treat likely side effects Must recognize individual responses to opioids may vary Response and side effects Hydrocodone vx. Oxycodone Sequential trials of different opioids – alone or in combination – may be necessary to optimize therapy

17 Common Analgesics Demerol Morphine Sulfate IR Percocet Dilaudid Lortab Opana IR Oxycodone Tramadol Butrans Morphine Sulfate ER OxyContin Exalgo Fentanyl patches Opana ER Methadone

18 Pure Opioid Agonists Pure Opioid agonist No ceiling effect for analgesia Single-entity for moderate to severe pain May be a role for combined opioids in certain subsets of patients

19 Current Regimen Opioid Naïve: Never been on opioids before Only been on opioids for a short time period or intermittently Opioid Tolerant Taking pain medications on a regular basis Dependent on amount of pain medication

20 Differences in older adult Experience higher peak and longer duration of drug action Age-related changes in drug distribution and elimination make more sensitive to sedation and respiratory distress Pain perceived differently Physiologic Psychological Cultural changes Altered presentations Aging does NOT increase Pain threshold Older adults (esp frail and old-old) at risk for too little or too much

21 General Approach Start pt on short acting Titrate up for pain relief Once stable convert to long acting Add amount of short acting for 24 hours Convert to long acting Continue short acting for breakthrough pain % of 24 hour total narcotic

22 Advantages of Long-Acting Opioids More predictable serum levels More predictable pain relief Avoids mini-withdrawals Easier to use; improved compliance Greater Patient satisfaction Less reinforcement of drug-taking behavior

23 Titration of Opioids Titrate to adequate pain control. Appropriate dose adjustments are critical to adequate pain control. Adjustments are indicated under the following circumstances If the patient has been taking more than 4 rescue doses per day If the patient rates pain as greater than 4/10 If the patient complains the pain is inadequately controlled

24 Dose Titration Based on two pieces of information: Calculation of the 24-hour narcotic total (this should be averaged over several days unless the patient has had a marked increase in pain in the prior 24-hour period of time) The stated average pain level (this should be averaged over several days unless the patient has had a marked increase in pain in the prior 24-hour period of time)

25 24-hour narcotic total: = 24 o fixed dose + 24 o rescue doses a patient is taking MSER 60 mg po bid with MSIR 15 mg po q1-2hrs prn for breakthrough. On history, he indicates that he is taking the sustained-release formulation as directed and 8 rescue doses in a 24-hour period of time.

26 The 24-hour narcotic total is: (60 mg x 2 doses) + (15 mg x 8 doses) = 120 mg mg = 240 mg.

27 Dose Titration Dose titration by a fixed percentage Moderate pain ( 5/6 ): increase 24 hour narcotic total by 25% Severe pain ( 7+ ): increase narcotic total by 50% Rescue dose: 10-15% of total dose offered Q 1-2 hours PRN Accommodate increase if pt frail, sick, or elderly

28 Case Study 1. Pt reports 6/10 pain, therefore he requires a 25 % increase in medication. 2. Pts 24 hour narcotic total = ___ mg morphine

29 Step 1: Increase dose by 25% 24 NT mg + (24 NT x.25) = New long acting dose

30 Step 2: Determine the new fixed dose New fixed dose / 2 doses per day = X mg bid

31 Step 3 Calculate the rescue dose 10% of NT mg = X mg New rescue order = MSIR X mg q2h prn

32 Old regimen MSER 60 mg bid MSIR 15 mg q 2 prn New regimen MSER 150 mg bid MSIR 30 mg q 2 prn

33 Case Study Pt reports 8/10 pain. What do you do?

34 Pt reports 8/10 pain, therefore he requires a 50 % increase in his medication. Pts 24 hour narcotic total = 240 mg morphine

35 Step 1: Increase dose by 50% 24 NT mg + (24 NT x.50) = 240 mg + ___ = ___ mg

36 Step 2: Determine the new fixed dose ? mg / 2 doses per day = ? mg

37 Step 3: Calculate the rescue dose 10% of new 24 NT = ___ mg New rescue order = MSIR ___ mg q2h prn

38 Old regimen MSER 60 mg bid MSIR 15 mg q 2 prn New regimen MSER 180 mg bid MSIR 30 mg q 2 prn

39 Equianalgesia Opioid Equianalgesic Dose Morphine 30 mg po Dilaudid 4-6 mg po Hydrocodone 30 mg po Oxycodone Codeine 180 mg po Opana Use conversion calculator

40 Or The ratio is 2:1 2 mg oral morphine per DAY ~ 1 mcq fentanyl patch 24-hour oral morphine dose (mg/day) Transdermal fentanyl dose (mcq/hour) Every additional 60 mg per dayAn additional 25 mcq per hour

41 Fentanyl Patch In pts currently on opioids, conversion factor for Morphine to Fentanyl is 2:1 Fentanyl patch is 2X more potent than morphine PO If the 24 hr narcotic total= 180 mg morphine Fentanyl dose= ___ mg (use nearest fentanyl patch size)

42 IV to PO conversion Now your patient is ready to go home but need to be converted to PO medication. Pt is on a morphine pain pump at a continuous infusion of 7.5 mg/hour and uses the bolus of 1 mg 6 times in the past 24 hours.

43 Case Study mg/hr X 24 = 180 mg morphine IV /24 2. IV Narcotic total = 186 mg IV 3. PO Narcotic total = 558 Opioid naïve: IV is 6X more potent than PO (1:6) Currently on opioid: IV is 3X more potent than PO (1:3)

44 4. Rescue dose is 10% = 60 mg morphine q 2 hours prn 5. Long acting dose = 280 mg morphine bid

45 Old regimen: 7.5 mg/hour CIV, with 1 mg q 10 minutes prn New Regimen: MSER 280 mg bid MSIR 60 mg q 2 prn

46 Case Study A patient with a pathologic fracture had satisfactory relief of pain with an IV dilaudid infusion of 3 mg per hour. You want to send her home on an equianalgesic dose of sustained release oral morphine (MS Contin or OraMorph SR given q12h, or Kadian q day). What is the correct dose?

47 Calculations 1. 3 mg/hr dilaudid = 72 mg IV dilaudid/24 hrs 2. Convert from dilaudid to morphine: 72 mg dilaudid IV X 5 = 360 mg IV morphine 3. Narcotic total = 360 mg IV morphine/24 hours

48 4. Multiply IV by 3 to obtain PO dose 360 x 3 = 1080 mg morphine in 24 hours PO 5. Breakthrough dose = 10 % of 24 hour narcotic total MSIR 30 mg, 3 tabs po q 2 prn Dilaudid 8 mg, 2 tab po q 2 prn

49 6. The q12h dose = 500 mg morphine SR PO q12h MS Contin 100 mg, 5 tabs po BID MS Contin 100 mg, 3 tabs po TID

50 Old regimen: 3 mg/hr dilaudid IV New regimen: MS Contin 100 mg, 5 tabs po BID MS Contin 100 mg, 3 tabs po TID Rescue dosing MSIR 30 mg, 3 tabs po q 2 prn or Dilaudid 8 mg, 2 tabs po q 2 prn

51 NARCAN !!!!! Narcan is a narcotic antagonist that works by blocking opiate receptor sites, which reverses or prevents toxic effects of narcotic (opioid) analgesics. DANGER : if given too quickly or if too much is given – severe life-threatening side effects can occur

52 Cardiovascular: Hyper-/hypotension, tachycardia, ventricular arrhythmia, cardiac arrest CNS: Irritability, anxiety, narcotic withdrawal, restlessness, seizure Gastrointestinal: Nausea, vomiting, diarrhea Neuromuscular & skeletal: Tremulousness Respiratory: Dyspnea, pulmonary edema

53 Use of Narcan in Narcotic overdose: I.V. (preferred), I.M., intratracheal, SubQ: mg every 2-3 minutes as needed; may need to repeat doses every minutes. If no response is observed after 10 mg, question the diagnosis. Note: Use mg increments in patients who are opioid dependent and in postoperative patients to avoid large cardiovascular changes.

54

55 Adjuvant Analgesics TCAs Desipramine Elavil SNRIs Cymbalta Savella Anticonvulsants Neurontin/Gabapentin Lyrica Joint/Bone pain: NSAIDS – potentiate opioids Methadone Lidoderm patches

56 TCAs and SNRIs Desipramine: 25 mg at bedtime, increase weekly to max dose of 150 mg daily Elavil: 25 mg at bedtime, max of 150 mg daily Cymbalta: 20 mg at bedtime, max dose 120 mg

57 Anticonvulsants Neurontin/Gabapentin Maximum daily dose: 3600 mg Start low and titrate up to max dose 100 mg qid Lyrica Maximum daily dose: 300 mg Start at 25 or 50 mg tid Problematic Side Effect: sedation

58 Bony or Metastatic pain NSAIDS Ibuprofen 800 mg tid Naproxen 600 mg bid Diclofenac 100 mg bid Steroids Medral Dose Pak

59 Methadone Possible duel mechanism of action Somatic and neuropathic pain relief Relatively inexpensive Available as a liquid Long half-life Accumulates with repeat doses with limited analgesic effect Complex pharmacokinetics No known active metabolites Conversion tables underestimate potency Cardiac Toxicity Recommend specialized training before prescribing as NP

60 Lidoderm Patch Lidocaine 5% in dermal patch On 12 hours, off 12 hours FDA approved for shingles Drug interaction and side effects are unlikely – most common is skin sensitivity Mechanical barrier decreases allodynia

61

62 Patient Education How the medication will impact their pain How to take medication. What the medication is treating Potential side effects, like constipation. When to call doctors office.

63 Patient Education How to store/protect their medication. Lock box or safe How to travel with their medication. What to do if/when medication is stolen or is lost/missing – CALL POLICE, FILE REPORT Consent for treatment

64 https://tnm.rxportal.sxc.com/rxclaim/TNM/PtMedMngtAgrmt.pdf Consent for Treatment Sources

65 Patient education Patients responsibility Clinicians responsibility Urine Drug Screen Use of drugs other than prescribed, and consequences

66 Re-evaluation Changes in pain (level, location, frequency, character) Level of function Average pain level Worst pain level Side effects Benefits Adherence to medication regimen (missed or extra doses)

67 Titrating off Opioids Indicated if pt unable to take medications safely If pts level of function is declining If medication is not effectively decreasing or controlling their level of pain Dose reduce in increments of 25% at a time No faster than hours.

68

69 State Controlled Substance Database Reports Frequent evaluations, with good documentation Lost or stolen drugs: Must report to police department Check for placement of fentanyl patches Urine Drug Screens – random, or when there is aberrant behavior Monitoring for abuse

70 Interpretation of UDS Results Important to understand what the results mean If question, call lab to check results

71 DrugMajor CmpdsMinor Cmpds Codeine Morphine Codeine Dihydrocodeine Hydrocodone Hydromorphone Hydrocodone Hydromorphone Dihydrocodeine Hydromorphone Oxycodone Oxymorphone Fentanyl **may not be picked in opiate screen Heroin/diamorphineMorphine6MAM by specific assay MarijuanaCarboxy-THC**many false +screen CocaineBenzoylecgonine

72 Results CANNABINOIDS (SCREEN) CANNABINOIDS (SCREEN) Positive Immunoassay(cut-off 20 ng/mL); confirmation to follow THC CONFIRMATION THC CONFIRMATION Positive for Carboxy-THC Cannabis metabolite cut-off 15 ng/mL COCAINE METAB (SCREEN) COCAINE METAB (SCREEN) Positive Immunoassay(cut-off 300 ng/mL); confirmation to follow BEG CONFIRMATION BEG CONFIRMATION Positive for Benzoylecgonine Cocaine metabolite cut-off 150 ng/mL

73 METHADONE (SCREEN) METHADONE (SCREEN) Negative Immunoassay(cut- off 300 ng/mL) OPIATE (SCREEN) OPIATE (SCREEN) Positive Immunoassay(cut-off 300 ng/mL); confirmation to follow GC/MS OPIATE CONFIRM GC/MS OPIATE CONFIRM Positive DIHYDROCODEINE DIHYDROCODEINE Negative CODEINE CODEINE Negative MORPHINE MORPHINE Negative HYDROCODONE HYDROCODONE Negative HYDROMORPHONE HYDROMORPHONE Negative OXYCODONE OXYCODONE Positive OXYMORPHONE OXYMORPHONE Positive OXYCODONE (SCREEN) OXYCODONE (SCREEN) Positive Immunoassay(cut- off 300 ng/mL); confirmation to follow

74 TRICYCLICS (SCREEN) TRICYCLICS (SCREEN) Negative Immunoassay(cut-off 300 ng/mL) ACETAMINOPHEN METABS ACETAMINOPHEN METABS Negative SALICYLATES SALICYLATES Negative PHENOTHIAZINES PHENOTHIAZINES Negative PROPOXYPHENE PROPOXYPHENE Negative Immunoassay(cut-off 300 ng/mL) METHANOL METHANOL Negative ETHANOL ETHANOL Negative ACETONE ACETONE Negative ISO-PROPANOL ISO-PROPANOL Negative

75 How to protect yourself Documentation UDS Consent for treatment Controlled Substance Database Report Frequent re-evaluation Communication (with your team and other providers) Patient Education Consistency

76 Addressing Aberrant Drug-Related Behavior General Management Principles – know laws and regulations – structure therapy to match perceived risk Proactive Strategies – communicate goals of therapy – provide written guidelines (treatment contract) – assess often Reactive Strategies – require frequent visits and small quantities of drug – use of urine toxicologies – long-acting drugs with no rescue doses – refer to addiction-medicine community (sponsor, program, addiction-medicine specialist, psychotherapist ) (Mironer et al, 2000; Portenoy et al, 1997; Passik et al, 2000)

77 Promoting Pain Relief and Preventing Abuse of Pain Medications: A Critical Balancing Act A joint statement from 21 health care organizations and the Drug Enforcement Agency, October 23, 2001 Undertreatment of pain is a serious problem in the US, including pain among patients with chronic conditions and those who are critically ill or near death Effective pain management is an integral and important aspect of quality medical care, and pain should be treated aggressively For many patients, opioid analgesics, when used as recommended by established pain management guidelines, are the most effective way to treat their pain, and often the only treatment option that provides significant relief

78

79 Considerations for the Nurse Practitioner Regulations – State law, Boards of Nursing and Medicine Safe Practice Requirements by the State Board of Nursing and Board of Medicine Prescriptions

80 Evaluation of Quantity and Chronicity Documented appropriate diagnosis Treatment of recognized medical indication Documented persistence of recognized medical indication Properly documented follow-up evaluation with appropriate continuing care

81 Writing Prescriptions Prescriptive authority varies state by state NPs denied any prescriptive authority Limited prescriptive authority – i.e. NP can only write 72 hours worth of pain medication Full prescriptive authority granted to NPs. For specifics visit: practitioners/nurse-practitioner-scope-of-practice- laws/ practitioners/nurse-practitioner-scope-of-practice- laws/

82 Safe Prescription Writing Pts Name, DOB, Current date Medication name Dose (mg, mcg) SIG : instructions about how medication is to be taken, how often, how many tablets, what route, frequency. DISP : amount of tablets or liquid to be dispensed. Should write it both as number and spelled out.

83 Vanderbilt University Medical Center Barbara Murphy, M.D. M. Rachel McDowell, APRN-BC 1956 The Vanderbilt Clinic Nashville, TN (615) Name: John Doe DOB: Date: RX: Morphine Sulfate Immediate Release 30 mg SIG: One tab PO Q 2 hours prn pain Disp: #56 (fifty six) (2 week supply) Max of 4 tabs in a 24 hour period 0 (ZERO) refills Signature: Mary Rachel McDowell, APRN-BC DEA #: MMM

84 Helpful Websites American Pain Society Partners against Pain International Association for the Study of Pain The Joint Commission American Academy of Pain

85 The following resources can provide important information on prescription pain medications, such as DEA schedule, appropriate prescribing and use, and information on how to prevent drug abuse and diversion: The American Pain Society (APS) American Academy of Pain Medicine (AAPM) American Society of Addiction Medicine (ASAM) Pain and Policy Studies Group for the University of Wisconsin Comprehensive Cancer Center United States Drug Enforcement Administration Taken from Partners Against Pain Web site

86 Food and Drug Administration The Substance Abuse and Mental Health Services Administration (SAMHSA) The National Association of Drug Diversion Investigators (NADDI) Local law enforcement Local addiction treatment specialists/centers Taken from Partners Against Pain Web site

87 References Katz, Warren, Rothenberg, Russell, 2005, Section 3: The Nature of Pain: Pathophysiology, JCR: Journal of Clinical Rheumatology, volume 11 (2) Supplement, April 2005, pp S11-S15, (Oct. 3, 2005) Cancer: principles and practice of oncology [edited by] Vincent T. DeVita, Jr., Samuel Hellman, Steven A. Rosenberg; 319 contributors. 6 th Nicholson, B.D., Neuropathic Pain: New Strategies to Improve Clinical Outcome, January 31, (Sept. 30, 2005)

88 Passik SD, Portenoy RK. Substance abuse issues in palliative care. In Berger A, Portenoy RK, Weissman D, eds. Principles and Practice of Supportive Oncology. 2nd ed. Philadelphia, PA: Lippincott-Raven Publishers; Passik SD, Portenoy RK: Substance abuse issues in psycho-oncology. In Holland J, et al. Handbook of Psycho-oncology. 2nd ed. Oxford: Oxford University Press; 1998: Loeser et al, 2001; Portenoy et al, 1996) Besson, JM. The neurobiology of pain. Lancet. 1999;353:

89


Download ppt "M. Rachel McDowell, RN, MSN, ACNP-BC Cancer Supportive Care Nurse Practitioner Vanderbilt-Ingram Cancer Center."

Similar presentations


Ads by Google